Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen PlanusFarzan Solimani, Michael Hertl, Rajkumar Savai et al.|Frontiers in Immunology|2019Cited by 116
TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planusThomas Schmidt, Michael Hertl, Farzan Solimani et al.|Journal of Allergy and Clinical Immunology|2018Cited by 83
Adjuvant high-dose intravenous immunoglobulins for recalcitrant erosive oral lichen planus: mixed clinical responsesArmin Bender, Michael Hertl, Caroline Fix et al.|European Journal of Dermatology|2018Cited by 9
271 Oral and cutaneous lichen planus exhibit two different T cell antigenic specificitiesThomas Schmidt, Michael Hertl, Ronja Stein et al.|Journal of Investigative Dermatology|2016Cited by 0